Drug

Tamoxifen

Established medicine

ResearchActive indication expansion

Also known as Emblon, Nolvadex, Nolvadex D, Soltamox+11 more

Emblon, Nolvadex, Nolvadex D, Soltamox, Tamofen, Tamoxifene, Tamoxifeno, Tamoxifène, (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine, 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, Barr - Tamoxifen Citrate, Tamoxifen Citrate, Tamoxifenum.

RxNorm10324 ChEMBLCHEMBL83 ATCL02BA01UNII094ZI81Y45

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Clinical trial2026-08-31Status changed to Completed · ClinicalTrials.gov

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Clinical trial2026-08-28Results expected Q4 2027 · ClinicalTrials.gov

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Clinical trial2026-08-28Results posted · ClinicalTrials.gov

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Clinical trial2026-08-10Results expected Q4 2032 · ClinicalTrials.gov

Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer

Clinical trial2026-08-04Results expected Q1 2027 · ClinicalTrials.gov

As chemo overtreatment comes into focus, Atossa bets on tamoxifen’s active form

Industry2026-07-27Drug Discovery & Development

Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Clinical trial2026-07-27Results expected Q1 2027 · ClinicalTrials.gov

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial

Clinical trial2026-07-27Results expected Q1 2028 · ClinicalTrials.gov

Variation in human gut microbiota impacts tamoxifen pharmacokinetics.

Research2024-11-25mBio

Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review.

Research2024-09-10Annals of internal medicine

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.

Research2024-05-01Clinical cancer research : an official journal of the American Association for Cancer Research

Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.

Research2021-03-18Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Tamoxifen

Aliases & brands

EmblonNolvadexNolvadex DSoltamoxTamofenTamoxifeneTamoxifenoTamoxifène(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-eneBarr - Tamoxifen CitrateTamoxifen CitrateTamoxifenum

RxNorm CUI

10324

ChEMBL ID

CHEMBL83

ATC codes

L02BA01

UNII

094ZI81Y45

Clinical trials

196 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

196

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

112

Completed

Discontinued

PHASE DISTRIBUTIONn = 196

Early Phase 12Phase 111Phase 1 / 26Phase 283Phase 2 / 33Phase 372Phase 48Phase N / A11

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study

Active, not recruitingPH IVNovartis Pharmaceuticalsn=1342030

An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR)

WithdrawnPH IVFred Hutchinson Cancer Center2025

Tamoxifen Versus Estradiol in the Prevention of Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Controlled Pilot Trial

WithdrawnPH IVVirginia Commonwealth University2024

Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users

CompletedPH IVOregon Health and Science Universityn=1092019

Clomiphene Citrate Versus Tamoxifen for Induction of Ovulation in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial

CompletedPH IVAin Shams Universityn=6002016

Recent completions

Trials that read out recently, adding to the completed evidence base.

Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

CompletedPH IIIrada Ibrahim-zadan=82026

Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory Breast Carcinoma

CompletedPH IICity of Hope Medical Centern=412025

Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen

CompletedN/AUruk Universityn=602025

Study to Evaluate the Effect of Metformin in the Prevention of Hyperglycemia in HR[+]/HER2[-] PIK3CA-mutation Advanced Breast Cancer Patients Treated With Alpelisib Plus Endocrine Therapy. Study Metallica

CompletedPH IIMedSIRn=692025

A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer

CompletedPH IIIKey trialETOP IBCSG Partners Foundationn=3,0662024

A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer

CompletedPH IIIKey trialETOP IBCSG Partners Foundationn=2,6722024

Research activity

7 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

19982025

Most influential

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Journal of the National Cancer Institute · 1998 · 3,331 cites

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

The New England journal of medicine · 2004 · 1,191 cites

Tmem119-EGFP and Tmem119-CreERT2 Transgenic Mice for Labeling and Manipulating Microglia.

eNeuro · 2019 · 223 cites

Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 49 cites

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2024 · 30 cites

Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review.

Annals of internal medicine · 2024 · 14 cites

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Breast Neoplasms4

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Estrogens

Studied across 4 of the same disease areas as Tamoxifen in the shared literature.

4 shared diseases1 shared paper

Dehydroepiandrosterone

Studied across 3 of the same disease areas as Tamoxifen in the shared literature.

3 shared diseases1 shared paper

Ospemifene

Studied across 3 of the same disease areas as Tamoxifen in the shared literature.

3 shared diseases1 shared paper

Exemestane

Studied across 2 of the same disease areas as Tamoxifen in the shared literature.

2 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials